Table 1.
Baseline Characteristics and Treatment Outcomes
| No. | Age, yr |
Sex | Clinical presentation | Diagnosis | Location | Size of tumor, mm | Pretreatment contrast harmonic imaging | RFA sessions | Initial response | Adverse event | Recurrence |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 72 | M | Incidental | NET | Pancreatic head | 16 | Hyperenhancement | 1 | CR | No | No |
| 2 | 34 | M | Hypoglycemia | Insulinoma | Pancreatic head | 12 | Hyperenhancement | 1 | CR | No | Yes (at 19 mo) |
| 3 | 38 | F | Cushing syndrome | Functioning adenoma | Adrenal gland | 28 | Hyperenhancement | 2 | PR | No | No |
| 4 | 21 | F | Incidental | SPN | Pancreatic head | 23 | Isoenhancement | 1 | PR | No | No |
| 5 | 53 | F | Incidental | SPN | Pancreatic tail | 20 | Isoenhancement | 1 | CR | No | No |
| 6 | 53 | F | Incidental | NET | Pancreatic body | 8 | Hyperenhancement | 1 | CR | No | No |
| 7 | 43 | M | Incidental | NET | Pancreatic body | 28 | Hyperenhancement | 2 | PR | No | No |
| 8 | 59 | M | Cushing syndrome | Functioning adenoma | Adrenal gland | 24 | Hyperenhancement | 3 | CR | No | No |
| 9 | 69 | F | Incidental | NET | Pancreatic body | 19 | Hyperenhancement | 2 | CR | No | No |
| 10 | 70 | M | Incidental | NET | Pancreatic body | 20 | Hyperenhancement | 1 | PR | No | No |
| 11 | 40 | M | Incidental | NET | Pancreatic body | 16 | Hyperenhancement | 1 | CR | No | No |
| 12 | 69 | F | Incidental | NET | Pancreatic head | 28 | Hyperenhancement | 3 | CR | No | No |
| 13 | 62 | F | Incidental | NET | Pancreatic head | 23 | Hyperenhancement | 3 | CR | Pancreatitis | No |
| 14 | 55 | M | Abdominal pain | HCC metastasis | Adrenal gland | 29 | Hyperenhancement | 3 | CR | No | No |
| 15 | 66 | M | Incidental | NET | Pancreatic body | 8 | Hyperenhancement | 1 | PR | No | No |
| 16 | 37 | F | Incidental | NET | Pancreatic head | 27 | Hyperenhancement | 2 | SD | Pancreatitis | No |
| 17 | 65 | M | Incidental | NET | Pancreatic body | 11 | Hyperenhancement | 1 | CR | No | No |
| 18 | 64 | M | Incidental | NET | Pancreatic tail | 11 | Hyperenhancement | 2 | CR | No | No |
| 19 | 63 | F | Incidental | NET | Pancreatic head | 20 | Hyperenhancement | 2 | CR | No | No |
RFA, radiofrequency ablation; M, male; F, female; NET, neuroendocrine tumor; HCC, hepatocellular carcinoma; CR, complete response; PR, partial response; SD, stable disease; SPN, solid pseudopapillary neoplasm.